A hereditary angioedema (HAE) patient with a rare gene mutation underwent several rounds of treatment adjustments and experienced multiple side effects while transitioning to off-label Takhzyro (lanadelumab‐flyo) over a period of 12 weeks, a study reports. …
Following a minor surgical procedure, a 70-year-old Indian man developed angioedema of the tongue that was likely triggered by an ACE inhibitor — a class of medicines often used to manage high blood pressure — a case report found. The patient had a…
Firazyr (icatibant), when used off-label to treat acute non-hereditary angioedema, can elicit different treatment responses, and its use — and best use — needs to be better understood by doctors treating attacks in this patient group, a real-world study from Australia reports. Biomarkers that could more easily distinguish…
The experimental therapy IONIS-PKK-LRx can significantly lower the number of monthly swelling attacks in patients with hereditary angioedema (HAE) type 1 and 2, according to top-line data from an ongoing Phase 2 trial. Newly announced data show the study (NCT04030598), sponsored by therapy developer Ionis Pharmaceuticals,…
Perceived stress affects how patients manage their care and influences their mental health, according to a study in people with hereditary angioedema (HAE) with C1 inhibitor (C1-INH) deficiency. Therefore, psychological interventions could increase the interest and involvement of these patients in their own care and…
A majority of women with hereditary angioedema (HAE) remain stable or even experience a reduction in disease severity after menopause, a small study reports. Improvements were mostly observed in women whose HAE was sensitive to estrogen fluctuations before…
A case report describes a man with confirmed COVID-19 who developed acute angioedema — a skin symptom that had not previously been associated with the virus — in his lips. “To our knowledge, there has not been…
Get regular updates to your inbox.